<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> are associated with deregulated production of myeloid cells </plain></SENT>
<SENT sid="1" pm="."><plain>The mechanisms underlying these disorders are not well defined </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We conducted a combination of molecular, cytogenetic, comparative-genomic-hybridization, and single-nucleotide-polymorphism analyses to identify a candidate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-suppressor gene common to patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo>, and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>The coding sequence of this gene, TET2, was determined in 320 patients </plain></SENT>
<SENT sid="4" pm="."><plain>We analyzed the consequences of deletions or mutations in TET2 with the use of in vitro clonal assays and transplantation of human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells into mice </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: We initially identified deletions or mutations in TET2 in three patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, in three of five patients with <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo>, in two patients with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and in one patient with <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>We selected the six patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> because they carried acquired rearrangements on chromosome 4q24; we selected the five patients with <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> because they carried a dominant clone in hematopoietic progenitor cells that was positive for the V617F mutation in the Janus kinase 2 (JAK2) gene </plain></SENT>
<SENT sid="7" pm="."><plain>TET2 defects were observed in 15 of 81 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (19%), in 24 of 198 patients with <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (12%) (with or without the JAK2 V617F mutation), in 5 of 21 patients with <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e> (24%), and in 2 of 9 patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (22%) </plain></SENT>
<SENT sid="8" pm="."><plain>TET2 defects were present in hematopoietic stem cells and preceded the JAK2 V617F mutation in the five samples from patients with <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> that we analyzed </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:hpo ids='HP_0001428'>Somatic mutations</z:hpo> in TET2 occur in about 15% of patients with various myeloid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
</text></document>